INmune Bio, Inc. (NASDAQ:INMB) Shares Purchased by Fermata Advisors LLC

Fermata Advisors LLC boosted its stake in INmune Bio, Inc. (NASDAQ:INMB) by 10.0% in the 4th quarter, Holdings Channel reports. The firm owned 46,997 shares of the company’s stock after purchasing an additional 4,267 shares during the period. Fermata Advisors LLC’s holdings in INmune Bio were worth $219,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Praetorian PR LLC boosted its position in shares of INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock worth $4,209,000 after buying an additional 295,800 shares during the period. CVI Holdings LLC acquired a new position in INmune Bio during the 2nd quarter worth about $5,260,000. Geode Capital Management LLC boosted its holdings in INmune Bio by 6.6% during the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock valued at $1,857,000 after acquiring an additional 21,262 shares during the period. State Street Corp grew its position in INmune Bio by 35.1% in the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after acquiring an additional 58,838 shares in the last quarter. Finally, Marshall Wace LLP grew its position in INmune Bio by 332.1% in the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after acquiring an additional 89,091 shares in the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

Analyst Upgrades and Downgrades

INMB has been the topic of several research reports. Raymond James started coverage on shares of INmune Bio in a research report on Friday, September 27th. They set an “outperform” rating and a $18.00 price target on the stock. Alliance Global Partners initiated coverage on shares of INmune Bio in a research report on Monday, October 21st. They issued a “buy” rating and a $20.00 price target for the company.

INmune Bio Stock Performance

Shares of INMB opened at $6.45 on Friday. INmune Bio, Inc. has a 1 year low of $4.32 and a 1 year high of $14.74. The stock has a market capitalization of $143.01 million, a PE ratio of -2.96 and a beta of 1.78. The stock has a 50-day simple moving average of $5.14 and a 200-day simple moving average of $6.10.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). During the same period in the prior year, the firm posted ($0.48) EPS. Analysts predict that INmune Bio, Inc. will post -2.24 EPS for the current year.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.